ASX - By Stock
|
IMU |
Re:
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
|
|
tin-tin
|
304 |
132K |
48 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
304
|
132K
|
48
|
|
ASX - By Stock
|
IMU |
Re:
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
|
|
tin-tin
|
304 |
132K |
26 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
304
|
132K
|
26
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene VAXINIA trial advances to Combination Cohort
|
|
tin-tin
|
153 |
75K |
105 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
153
|
75K
|
105
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Letter to Shareholders
|
|
tin-tin
|
111 |
60K |
32 |
08/01/23 |
08/01/23 |
ASX - By Stock
|
111
|
60K
|
32
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
19 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
14K
|
6.7M
|
19
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene onCARlytics with blinatumomab SITC presentation
|
|
tin-tin
|
23 |
12K |
42 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
23
|
12K
|
42
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
4 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
14K
|
6.7M
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
34 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
14K
|
6.7M
|
34
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
32 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
14K
|
6.7M
|
32
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
tin-tin
|
208 |
59K |
16 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
208
|
59K
|
16
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
tin-tin
|
208 |
59K |
14 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
208
|
59K
|
14
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
36 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
14K
|
6.7M
|
36
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
84 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
14K
|
6.7M
|
84
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
|
|
tin-tin
|
11 |
8.0K |
21 |
13/10/22 |
13/10/22 |
ASX - By Stock
|
11
|
8.0K
|
21
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
95 |
08/10/22 |
08/10/22 |
ASX - By Stock
|
14K
|
6.7M
|
95
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Preclinical trial of ALA iNKT therapy and IMU onCARlytics
|
|
tin-tin
|
75 |
42K |
16 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
75
|
42K
|
16
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Analysts Reports (Imugene)
|
|
tin-tin
|
338 |
196K |
24 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
338
|
196K
|
24
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Analysts Reports (Imugene)
|
|
tin-tin
|
338 |
196K |
12 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
338
|
196K
|
12
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Analysts Reports (Imugene)
|
|
tin-tin
|
338 |
196K |
27 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
338
|
196K
|
27
|
|
ASX - By Stock
|
IMU |
Re:
Ann: First patient IV dosed in VAXINIA Phase 1 clinical trial
|
|
tin-tin
|
59 |
35K |
48 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
59
|
35K
|
48
|
|
ASX - By Stock
|
IMU |
Re:
Ann: OGTR grants VAXINIA DIR licence allowing trial expansion
|
|
tin-tin
|
137 |
74K |
36 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
137
|
74K
|
36
|
|
ASX - By Stock
|
IMU |
Re:
Ann: OGTR grants VAXINIA DIR licence allowing trial expansion
|
|
tin-tin
|
137 |
74K |
53 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
137
|
74K
|
53
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
10 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
14K
|
6.7M
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
9 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
14K
|
6.7M
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene doses first patient in nextHERIZON Phase 2 trial
|
|
tin-tin
|
60 |
37K |
51 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
60
|
37K
|
51
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene doses first patient in nextHERIZON Phase 2 trial
|
|
tin-tin
|
60 |
37K |
93 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
60
|
37K
|
93
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
tin-tin
|
14K |
6.7M |
30 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
14K
|
6.7M
|
30
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
|
|
tin-tin
|
73 |
56K |
50 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
73
|
56K
|
50
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
|
|
tin-tin
|
73 |
56K |
43 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
73
|
56K
|
43
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
|
|
tin-tin
|
73 |
56K |
156 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
73
|
56K
|
156
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
tin-tin
|
185 |
53K |
31 |
29/07/22 |
29/07/22 |
ASX - By Stock
|
185
|
53K
|
31
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
129 |
10/07/22 |
10/07/22 |
ASX - By Stock
|
24K
|
12M
|
129
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
82 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
24K
|
12M
|
82
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Analysts Reports (Imugene)
|
|
tin-tin
|
338 |
196K |
19 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
338
|
196K
|
19
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Analysts Reports (Imugene)
|
|
tin-tin
|
338 |
196K |
49 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
338
|
196K
|
49
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
49 |
27/06/22 |
27/06/22 |
ASX - By Stock
|
24K
|
12M
|
49
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
37 |
26/06/22 |
26/06/22 |
ASX - By Stock
|
24K
|
12M
|
37
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
64 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
24K
|
12M
|
64
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
19 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
24K
|
12M
|
19
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
82 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
24K
|
12M
|
82
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
45 |
12/06/22 |
12/06/22 |
ASX - By Stock
|
24K
|
12M
|
45
|
|
ASX - By Stock
|
IMU |
Re:
Ann: IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
|
|
tin-tin
|
159 |
94K |
32 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
159
|
94K
|
32
|
|
ASX - By Stock
|
IMU |
Re:
Ann: IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
|
|
tin-tin
|
159 |
94K |
69 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
159
|
94K
|
69
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
5 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
24K
|
12M
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
tin-tin
|
24K |
12M |
89 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
24K
|
12M
|
89
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Change of Director's Interest Notice - DT
|
|
tin-tin
|
66 |
20K |
11 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
66
|
20K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Ann: IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
|
|
tin-tin
|
81 |
47K |
51 |
10/05/22 |
10/05/22 |
ASX - By Stock
|
81
|
47K
|
51
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Q3 FY22 Quarter Update Conference Call Details /Presentation
|
|
tin-tin
|
87 |
26K |
14 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
87
|
26K
|
14
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Q3 FY22 Quarter Update Conference Call Details /Presentation
|
|
tin-tin
|
87 |
26K |
11 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
87
|
26K
|
11
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Q3 FY22 Quarter Update Conference Call Details /Presentation
|
|
tin-tin
|
87 |
26K |
20 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
87
|
26K
|
20
|
|